Oxidative Stress and Inflammatory Biomarkers in People with Methamphetamine Use Disorder

Cognitive functioning of adolescents using Methamphetamine: The impact of inflammatory and oxidative processes

BACKGROUND

Methamphetamine is a substance that causes neurotoxicity and its use is increasing in recent years. Literature highlights cognitive impairment resulting from Methamphetamine use. The aim of the present study is to evaluate the relationship between cognitive impairment and inflammatory processes in adolescents with Methamphetamine use disorder.

METHODS

The study included 69 adolescents aged 15-19 years, comprising 37 participants with Methamphetamine Use Disorder and 32 healthy controls. Central Nervous System Vital Signs was used to detect cognitive impairment. Childhood Trauma Questionnaire-33 and The Children's Depression Inventory scales were used. In addition, venous blood was collected from the volunteers. Biochemical parameters (IL-1beta, IL-6, TNF-a, BDNF, FAM19A5, TAS, TOS) were analyzed.

RESULTS

Our study showed that (I) IL-6 and TNF-a levels of Methamphetamine users were lower than the healthy group; (II) BDNF levels of Methamphetamine users were higher than the healthy group; (III) mean Neurocognitive Index in cognitive tests of Methamphetamine using adolescents was negatively correlated with duration of Methamphetamine use and BDNF levels.

CONCLUSIONS

Our study suggests that Methamphetamine use may have a negative effect on cognitive functions.

Morin Mitigates Methamphetamine-Induced Neurotoxicity: Effects on Motor and Cognitive Function

Introduction

Neurodegenerative diseases are a major public health concern, often associated with motor and cognitive deficits. Methamphetamine (METH) exposure induces lasting neurological impairment and neuronal loss. This study evaluated Morin's potential to reverse these effects, focusing on motor and cognitive dysfunction in METH-induced neurotoxicity.

Methods

Adult rats were randomly assigned into seven groups, including control, Morin-only, METH-only, METH plus fluoxetine, and three groups receiving METH followed by varying doses of Morin. Following METH induction, Morin, a natural flavonoid with antioxidant properties, was administered to rats. Neurobehavioral tests evaluated motor and cognitive function; serum levels of oxidative stress markers, inflammatory cytokines, dopamine, and acetylcholine were measured. Histological and immunohistochemical analyses of the basal ganglia were performed to evaluate neuronal integrity.

Results

METH exposure significantly elevated oxidative stress and inflammatory markers, altered neurotransmitter levels, and impaired both motor and cognitive performance, coinciding with neuronal loss in the basal ganglia. Treatment with Morin ameliorated these effects in a dose-dependent manner. Neuronal degenerative features noted in the METH-only group were significantly ameliorated in the Morin-treated groups.

Conclusion

These findings indicate that Morin mitigates METH-induced neurotoxicity by reducing oxidative stress, and suppressing inflammation. This study demonstrates Morin's potential as a treatment option for the neurological effects of methamphetamine misuse.

Association of Cognitive Impairment and Peripheral Inflammation in Methamphetamine-dependent Patients: A Cross-sectional Study on Neuroinflammatory Markers TNF-α and IL-6

Objective

To investigate the cognitive impairment and peripheral inflammation induced by methamphetamine (METH) and their association in METH abusers.

Methods

The cross-sectional study included 100 METH-dependent patients and 100 healthy controls. Cognitive screening was conducted using the Thai version of the Montreal Cognitive Assessment (MoCA-T). Thirty normal controls and 30 METH-dependent patients were randomly selected for blood collection to measure inflammatory markers, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, using a quantitative enzyme-linked immunosorbent assay method.

Results

METH-dependent patients had significantly poorer MoCA-T scores and higher levels of blood inflammatory markers compared to healthy controls. Demographic characteristics, METH use patterns, and proinflammatory cytokines were associated with cognitive impairment. The MoCA-T score was negatively associated with plasma TNF-α and IL-6 levels.

Conclusion

METH-associated cognitive decline is correlated with elevated plasma levels of TNF-α and IL-6 cytokines, indicating the involvement of specific neuroinflammatory pathways in neurocognitive dysfunction. These insights could pave the way for novel therapeutic strategies aimed at mitigating neuroinflammation, potentially improving outcomes for individuals with METH addiction.

Formication with destruction of the nasal septum: A rare case report

Delusions of parasitosis are known by several names, one of which is formication. It is an uncommon psychiatric disorder listed in the DSM V under the classification of delusional disorders. Patients experience an established, incorrect belief that they have an infection of living organisms such as parasites. There are two types of delusions of parasitosis, primary and secondary. In the primary form, the symptom is the delusion of a parasitic infection without secondary cause. The secondary form includes this symptom as well as additional psychiatric disorder, drug abuse, or medical illness. Patients often seek consultation with dental providers for dental pain with underlying medical conditions. This is a case report of a 35-year-old male with comorbid HIV and Hepatitis B disease, as reported by the patient, who sought care with a dental urgent care clinic with a chief complaint of dental pain and a presentation of collapse, atrophy, and ebbing of the nasal septum due to patient admitted formication. An accurate and complete medical was not obtainable from the patient who was subsequently lost to follow-up. Patient symptoms, clinical examination, and differential diagnosis rationale are presented. Further, information on cocaine and methamphetamine is also discussed. Followed by the conclusion that advocates for the usefulness of this case report for primary medical and dental providers. Recognition of concurrent medical and dental conditions will expedite collaborative care, patient referral, and treatment options that support best practices in patient care.

A Mechanistic Review on Toxicity Effects of Methamphetamine

Persistent methamphetamine use causes many toxic effects in various organs, including the brain, heart, liver, kidney and eyes. The extent of its toxicity depends on numerous pharmacological factors, including route of administration, dose, genetic polymorphism related to drug metabolism and polysubstance abuse. Several molecular pathways have been proposed to activate oxidative stress, inflammation and apoptosis: B-cell lymphoma protein 2 (Bcl-2)-associated X (Bax)/Bcl2/caspase-3, nuclear factor erythroid 2-related factor (Nrf2)/heme oxygenase-1 (HO-1), protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/p70S6K, trace amine-associated receptor 1 (TAAR1)/cAMP/lysyl oxidase, Sigmar1/ cAMP response element-binding protein (CREB)/mitochondrial fission-1 protein (Fis1), NADPH-Oxidase-2 (NOX-2), renal autophagy pathway, vascular endothelial growth factor (VEGF)/phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (Akt)/endothelial nitric oxide synthase (eNOS), Nupr1/Chop/P53/PUMA/Beclin1 and Toll-like receptor (TLR)4/MyD88/TRAF6 pathways. The activation promotes pathological changes, including the disruption of the blood-brain barrier, myocardial infarction, cardiomyopathy, acute liver failure, acute kidney injury, chronic kidney disease, keratitis, retinopathy and vision loss. This review revisits the pharmacological profiles of methamphetamine and its effects on the brain, heart, liver, eyes, kidneys and endothelium. Understanding the mechanisms of methamphetamine toxicity is essential in developing treatment strategies to reverse or attenuate the progress of methamphetamine-associated organ damage.

Ten-year cardiovascular disease risk and related factors in lifetime marijuana use with comorbid methamphetamine-associated psychotic disorder: a QRISK®3 study

BACKGROUND

Methamphetamine use and related direct and indirect problems are increasing all over the world. The coexistence of lifetime marijuana use (LMU) and methamphetamine use disorder (MUD) may also be accompanied by psychotic symptoms (MAP). Methamphetamine and marijuana use are known to pose risks for cardiovascular diseases (CVDs). However, ten-year CVD risk and inflammation markers of LMU-MUD (non-psychosis group) and LMU-MAP (psychosis group) subjects and the relationship of various sociodemographic and clinical variables with these markers have not yet been examined.

METHODS

Thirty-two male subjects were included in non-psychosis group and 72 male subjects in psychosis group. Sociodemographic and clinical characteristics were recorded. Psychotic symptom severity of psychosis group subjects was measured. The ten-year CVD risk was calculated using QRISK®3 model.

RESULTS

Age, cigarettes/pack-years, alcohol use onset age, drug use onset age, methamphetamine use onset age, duration of methamphetamine use, education and marital status of the groups were similar (p > 0.05). There was a statistical difference between the non-psychosis and psychosis groups in terms of self-mutilation history (p < 0.001), suicidal attempt history (p = 0.007), homicidal attempt history (p = 0.002), psychiatric hospitalization history (p = 0.010). Ten-year QRISK®3 score was 4.90 ± 9.30 in the psychosis group, while it was 1.60 ± 1.43 in the non-psychosis group (p = 0.004). The mean heart age of the psychosis group was 14 years higher than their chronological age, while the mean heart age of the non-psychosis group was 8 years higher. Neutrophil to lymphocyte ratio (NLR) (p = 0.003) was higher in the psychosis group. A significant correlation was detected between ten-year QRISK®3 and positive psychotic symptoms in the psychosis group (r = 0.274, p = 0.020). Regression analysis showed that self-mutilation history, NLR and relative risk obtained from QRISK®3 can be used to distinguish non-psychosis group and psychosis group subjects (sensitivity = 91.7; Nagelkerke R2 0.438; p = 0.001).

CONCLUSIONS

This study is important as it demonstrates for the first time that among the subjects using marijuana and methamphetamine, those with psychotic symptoms have a higher NLR and ten-year CVD risk.

Mechanisms and treatments of methamphetamine and HIV-1 co-induced neurotoxicity: a systematic review

Combination antiretroviral therapy (cART) has dramatically reduced mortality in people with human immunodeficiency virus (HIV), but it does not completely eradicate the virus from the brain. Patients with long-term HIV-1 infection often show neurocognitive impairment, which severely affects the quality of life of those infected. Methamphetamine (METH) users are at a significantly higher risk of contracting HIV-1 through behaviors such as engaging in high-risk sex or sharing needles, which can lead to transmission of the virus. In addition, HIV-1-infected individuals who abuse METH exhibit higher viral loads and more severe cognitive dysfunction, suggesting that METH exacerbates the neurotoxicity associated with HIV-1. Therefore, this review focuses on various mechanisms underlying METH and HIV-1 infection co-induced neurotoxicity and existing interventions targeting the sigma 1 receptor, dopamine transporter protein, and other relevant targets are explored. The findings of this review are envisaged to systematically establish a theoretical framework for METH abuse and HIV-1 infection co-induced neurotoxicity, and to suggest novel clinical treatment targets.

Can Methamphetamine-Induced Cardiotoxicity be Ameliorated by Aerobic Training and Nutrition Bio-shield Superfood Supplementation in Rats After Withdrawal?

The abuse of methamphetamine is a significant threat to cardiovascular health and has detrimental effects on the myocardium. The present study aims to explore potential interventions that can mitigate myocardial pyroptosis in rats following methamphetamine withdrawal. A total of 104 male Wistar rats were randomly assigned to eight groups. The rats underwent a methamphetamine administration protocol, receiving intraperitoneal injections of 10 mg/kg during the 1st week, followed by a weekly dose escalation of 1 mg/kg from the second to the 6th week and two times per day. Concurrently, the rats engaged in 6 weeks of moderate-intensity treadmill aerobic training, lasting 60 min per day, 5 days a week. Simultaneously, the Nutrition bio-shield Superfood (NBS) supplement was administered at a dosage of 25 g/kg daily for 6 weeks. The study assessed the expression levels of Caspase-1, Interleukin-1beta (IL-1β), and Interleukin-18 (IL-18) genes in myocardial tissue. Data analysis utilized a one-way analysis of variance (p ≤ 0.05). The findings revealed that methamphetamine usage significantly elevated the expression of Caspase-1, IL-1β, and IL-18 genes (p ≤ 0.05). Conversely, methamphetamine withdrawal led to a notable reduction in the expression of these genes (p ≤ 0.05). Noteworthy reductions in Caspase-1, IL-1β, and IL-18 expression were observed following aerobic training, supplementation, and the combined approach (p ≤ 0.05). The chronic use of methamphetamine was associated with cardiac tissue damage. This study highlights the potential of aerobic training and NBS Superfood supplementation in mitigating the harmful effects of methamphetamine-induced myocardial pyroptosis. The observed reductions in gene expression levels indicate promising interventions to address the cardiovascular consequences of methamphetamine abuse. The findings of this study suggest that a combination of aerobic exercise and NBS Superfood supplementation can provide a promising approach to mitigate the deleterious effects of methamphetamine on the heart. These findings can be useful for healthcare professionals and policymakers to design effective interventions to prevent and manage the adverse effects of methamphetamine abuse.

Evaluation of Complete Blood Cell Count Parameters and Their Role in Inflammation in Patients with Methamphetamine and Synthetic Cannabis Use Disorder

Background

The aim of this study was to compare the complete blood cell count parameters of patients with methamphetamine and synthetic cannabis use disorder (MCUD), a condition that has recently exhibited a gradual increase in prevalence, with those of healthy subjects.

Methods

In total, 76 patients diagnosed with MCUD and 78 healthy controls were included in the study. Venous blood samples were collected from all participants at presentation for laboratory examination.

Results

The rate of mono- and poly-substance users in the patient group was 14.5% and 85.5%, respectively. The average duration of methamphetamine (METH) use in the patient group is 3.0 ± 1.9 years. White blood cell (P < .001), PLT (P = .005), monocyte count (P < .001), basophil count (P < .001), neutrophil count (P < .001), lymphocyte count (P < .001) basophil/lymphocyte ratio (BLR) (P = .04), SII (P = .006), and SIRI (P = .001) values were significantly higher. In contrast Hgb (P = .043), Hct (P = .002), monocyte percentage (P = .004), and RBC (P = .021) values were significantly lower in the MCUD group compared to the control group. There was a significant positive correlation between neutrophil/lymphocyte ratio and platelet/lymphocyte ratio (r = .552 P < .001) and between systemic immune inflammatory index (SII) and systemic inflammation response index (SIRI) (r = 0.580 P < .001).

Conclusion

Methamphetamine and cannabis may affect the levels of inflammatory markers and SII and SIRI values through various mechanisms. To the best of our knowledge, this is the first study in the relevant literature, which investigated SII and SIRI values in patients with MCUD, therefore, the results can contribute to the future development of immune system-related markers in this field.